MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)GlobeNewsWire • 09/28/26
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)GlobeNewsWire • 09/24/26
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patientsGlobeNewsWire • 07/15/26
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma TreatmentGlobeNewsWire • 06/08/26
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)GlobeNewsWire • 05/26/26
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical TranslationGlobeNewsWire • 04/27/26
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patientsGlobeNewsWire • 01/29/26
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral NeuropathyGlobeNewsWire • 12/18/25
MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MNDGlobeNewsWire • 12/08/25
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory AdvisorGlobeNewsWire • 11/18/25
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough AwardsGlobeNewsWire • 11/06/25
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed PublicationGlobeNewsWire • 10/30/25
MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 09/03/25
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 MillionGlobeNewsWire • 07/31/25
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical TrialsGlobeNewsWire • 07/24/25